Opinion|Videos|August 14, 2024
Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
A panel of experts on chronic myeloid leukemia discuss common patient concerns, adverse effect considerations, and best practices for setting clear expectations.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are some of the most common concerns or questions newly diagnosed CML patients may have about their initial treatment plan?
- What are some common adverse effects or tolerability challenges patients may experience with their initial treatment plan?
- What is your best practice to set clear expectations with your patients on what they may experience along their CML journey?
Advertisement
Related to this article
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.
Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.
Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.
Diagnosed with leukemia at 8 years old, Harper feared that losing her hair would change who she was. She reflects on body image, confidence and finding a sense of herself during cancer treatment.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
What New KRAS Drug Data From ESMO 2026 Mean for Patients
3
What Liquid Biopsy and ESR1 Mutations Mean in Breast Cancer
4
Imdelltra Plus Imfinzi Extends Survival in Small Cell Lung Cancer
5